Product logins

Find logins to all Clarivate products below.


Chronic Heart Failure | Treatment Algorithms: Claims Data Analysis | US | 2017

First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, oral beta blocker, and oral diuretic. Second- or third-line treatments is often needed to better manage the disease. Physicians have numerous drug classes to choose from, most of which have many drug options. The CHF market is heavily genericized, as such physicians are less constrained by pricing pressures. The CHF Treatment Algorithm offers insight into prescribing patterns following the increase in generic drug availability. That said, there are a few branded agents that jostle for patient share in this crowded sector. Small patient shares for such a prevalent indication can translate into significant commercial positions.

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…